Search Results
Search this site
658 results found with an empty search
- Health Canada licenses Light AI’s QuickScan Strep A smartphone software for suspected strep throat assessment
The Canadian authorisation moves Light AI’s AI-enabled throat-image analysis platform from investigational development into its first regulated market, providing healthcare professionals with a software-based tool to support assessment of suspected Group A Streptococcus infection. Health Canada has issued a medical device licence for Light AI’s QuickScan Strep A, a smartphone-enabled Software as a Medical Device designed to assist healthcare professionals in assessing patients with suspected Group A Streptococcus pharyngitis. The authorisation represents a material regulatory step for Light AI, whose platform analyses throat images using artificial intelligence without requiring proprietary diagnostic hardware. Field Content Alert Type Drug Approval Drug Name QuickScan Strep A Indication Software as a Medical Device intended to assist healthcare professionals in the assessment of patients presenting with symptoms consistent with pharyngitis and suspected Group A Streptococcus (Strep A) infection. Therapy Area(s) Infectious diseases; Primary care; Diagnostics Geography Canada (Health Canada) What Happened Health Canada has issued Light AI a medical device licence for QuickScan Strep A, the company’s AI-enabled Software as a Medical Device for assessment of suspected Group A Streptococcus pharyngitis. The platform is designed to analyse throat images captured using compatible smart devices and provide an AI-supported assessment. The authorisation follows Light AI’s completion of ISO 13485:2016 and Medical Device Single Audit Program certification in June 2026, which supported its planned Canadian regulatory submission. Earlier company disclosures described QuickScan Strep A as investigational and unavailable for commercial diagnostic use, meaning the Health Canada licence represents a change in its Canadian regulatory status. (Stockwatch) Why It Matters Strep A and viral pharyngitis can present with overlapping symptoms, while determining whether a bacterial infection is present can influence subsequent testing and treatment decisions. QuickScan’s software-based approach is intended to provide healthcare professionals with an additional assessment tool using compatible smart-device images rather than proprietary diagnostic hardware; the Health Canada licence permits regulated Canadian use within the authorised indication but does not by itself establish reimbursement or widespread clinical adoption. Supporting Context Light AI has been pursuing parallel regulatory development in Canada and the US. In June 2026, it initiated a US pivotal clinical trial comparing QuickScan Strep A with throat culture to generate evidence for a planned FDA Class II submission; the FDA programme remains separate from the Canadian authorisation. (Light AI) Key Takeaway Health Canada’s licence gives Light AI its first regulated pathway for QuickScan Strep A as an AI-supported smartphone tool for assessing suspected Strep A infection. What to Watch Canadian commercial availability and clinical deployment, alongside completion of Light AI’s ongoing US pivotal study and any subsequent FDA submission. (Light AI) Primary Source Light AI / Health Canada medical device licensing announcement Relevant Date 14 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- PTC Therapeutics wins auction for Sangamo’s ST-920 Fabry gene therapy in deal worth up to $211 million
The acquisition would add a BLA-stage, one-time AAV gene therapy to PTC’s rare disease portfolio, with a rolling US submission expected to complete in the fourth quarter of 2026. PTC Therapeutics has been selected as the winning bidder in a competitive bankruptcy auction to acquire ST-920, Sangamo Therapeutics’ BLA-stage AAV gene therapy for Fabry disease, for $111 million upfront plus up to $100 million in regulatory milestones. The transaction gives PTC a late-stage rare disease programme that could use its existing gene therapy and global commercial infrastructure, with a potential US launch in 2027 if the BLA is completed and subsequently approved. Field Content Alert Type Deal Companies PTC Therapeutics; Sangamo Therapeutics Deal Type Asset acquisition following competitive bankruptcy auction Asset or Company ST-920 (isaralgagene civaparvovec) Therapy Area(s) Rare disease; Fabry disease Technology or Modality One-time AAV gene therapy Deal Value $111 million upfront, plus up to $100 million in regulatory milestone payments, giving a maximum potential transaction value of $211 million. The additional $100 million is contingent and should not be treated as guaranteed consideration. (Yahoo Finance) Development Stage BLA-stage; rolling US Biologics License Application submission underway Geography Global What Happened On 12 August 2026, PTC Therapeutics announced that it had been selected as the winning bidder to acquire ST-920 from Sangamo Therapeutics through a competitive bankruptcy auction. PTC will pay $111 million upfront and could pay a further $100 million tied to regulatory milestones. ST-920 is a one-time AAV gene therapy designed to deliver a functional copy of the GLA gene in people with Fabry disease. The programme is already at BLA stage, with completion of the rolling US submission expected in the fourth quarter of 2026. The acquisition remains subject to the applicable bankruptcy court approval and closing process. (Yahoo Finance) Why It Matters PTC is acquiring a regulatory-stage gene therapy rather than an early clinical programme, limiting the additional development required before a potential US regulatory decision. ST-920 also fits PTC’s existing focus on rare diseases and gene therapy, allowing the company to use established infrastructure rather than building a new commercial organisation specifically for the asset. PTC has identified the programme as an opportunity to support short- and intermediate-term revenue growth, although this remains dependent on regulatory approval and successful commercialisation. (Yahoo Finance) Supporting Context Fabry disease is an X-linked lysosomal disorder caused by variants in the GLA gene, resulting in deficient alpha-galactosidase A activity and progressive accumulation of disease-associated substrates. ST-920 has been evaluated in the Phase I/II STAAR study and is designed to enable sustained production of alpha-galactosidase A following a single administration. (Sangamo) Strategic Rationale PTC gains a BLA-stage rare disease asset that complements its existing global commercial and gene therapy capabilities without requiring the lengthy development timeline associated with acquiring an earlier-stage programme. Sangamo’s bankruptcy process, meanwhile, provides a mechanism to monetise the ST-920 programme through the asset sale. Potential Impact If the BLA is successfully completed and FDA approval follows, ST-920 could give PTC a commercial-stage Fabry disease gene therapy as early as 2027. Its eventual clinical and commercial contribution will depend on regulatory review, the durability and safety of the therapy and adoption within the existing Fabry treatment landscape. Key Takeaway The acquisition gives PTC a BLA-stage Fabry gene therapy with near-term regulatory potential for $111 million upfront, substantially accelerating its opportunity to add another commercial rare disease product. What to Watch Bankruptcy court approval and transaction closing, completion of the rolling BLA in the fourth quarter of 2026, subsequent FDA review and whether ST-920 remains on track for a potential 2027 US launch. (Yahoo Finance) Primary Source PTC Therapeutics acquisition announcement Relevant Date 12 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA grants accelerated approval to Zenbexus combination for previously treated multiple myeloma
The approval provides adults who have received at least one prior line of therapy with a new iberdomide-based combination, supported by higher minimal residual disease-negative complete response rates than the comparator regimen in EXCALIBER-RRMM. The US Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The approval introduces an iberdomide-based treatment option earlier in the relapsed or refractory multiple myeloma pathway, with continued approval dependent on verification of clinical benefit. Field Content Alert Type Drug Approval Drug Name Zenbexus (iberdomide) Indication In combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. (U.S. Food and Drug Administration) Therapy Area(s) Haematology; Oncology; Multiple myeloma Geography United States (FDA) What Happened On 13 August 2026, the FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone. The approved population comprises adults with multiple myeloma previously treated with at least one line containing a proteasome inhibitor and an immunomodulatory agent. Iberdomide is administered orally at 1 mg once daily on days 1–21 of each 28-day cycle alongside subcutaneous daratumumab and hyaluronidase-fihj and dexamethasone, with treatment continuing until disease progression or unacceptable toxicity. (U.S. Food and Drug Administration) Why It Matters The approval makes an iberdomide-based regimen available to patients after at least one prior line of therapy, adding another treatment option in relapsed or refractory multiple myeloma. In EXCALIBER-RRMM, the regimen achieved a 41% MRD-negative complete response rate, compared with 21% for daratumumab and hyaluronidase-fihj, bortezomib and dexamethasone (DVd); however, accelerated approval is based on this surrogate endpoint and clinical benefit still requires confirmation. (U.S. Food and Drug Administration) Supporting Context EXCALIBER-RRMM was a two-stage, randomised, multicentre, open-label trial involving 939 adults with relapsed or refractory multiple myeloma previously treated with one or two lines of therapy. Patients whose disease was refractory to previous anti-CD38 monoclonal antibody therapy or bortezomib were excluded. The primary efficacy analysis compared 207 patients receiving IberDd with 213 receiving DVd. (U.S. Food and Drug Administration) Key Takeaway FDA accelerated approval adds iberdomide to the treatment options available after at least one previous multiple myeloma regimen, based on a significantly higher MRD-negative complete response rate versus DVd. (U.S. Food and Drug Administration) What to Watch Because Zenbexus received accelerated approval, continued approval for this indication may depend on confirmation of clinical benefit. The prescribing information also carries a boxed warning for embryo-fetal toxicity and serious venous and arterial thromboembolism, and iberdomide is available only through the ZENBEXUS REMS restricted distribution programme because of embryo-fetal toxicity risk. (U.S. Food and Drug Administration) Primary Source https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone Relevant Date 13 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- HanchorBio partners with Taiwan Cancer Moonshot team to advance precision immunotherapy development
The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research. HanchorBio has entered into a strategic research collaboration with Taiwan's Cancer Moonshot team to evaluate precision immunotherapy approaches using the company's immuno-oncology pipeline and biomarker capabilities. The partnership is intended to strengthen translational research and patient selection strategies while supporting the clinical development of HanchorBio's next-generation immunotherapies. Field Content Alert Type Deal Companies HanchorBio; Taiwan Cancer Moonshot team Deal Type Strategic research collaboration Asset or Company HanchorBio's precision immunotherapy pipeline, including HCB101 and associated biomarker research programmes Therapy Area(s) Oncology; Precision medicine; Immuno-oncology Technology or Modality Multi-target immunotherapy platform and biomarker-driven precision oncology Geography Taiwan What Happened HanchorBio announced a strategic collaboration with Taiwan's Cancer Moonshot team to advance precision immunotherapy research. The collaboration is designed to integrate HanchorBio's immunotherapy platform with the Cancer Moonshot programme's clinical and translational research capabilities to improve biomarker-driven patient selection and support future clinical development. The announcement relates to a research partnership rather than a licensing agreement or acquisition, and no financial terms were disclosed. Why It Matters The partnership strengthens the translational research infrastructure supporting HanchorBio's immunotherapy programmes and could improve the identification of patients most likely to benefit from targeted immunotherapies. It also demonstrates increasing collaboration between biotechnology companies and national precision medicine initiatives to accelerate oncology drug development. Supporting Context HanchorBio is developing a portfolio of next-generation immunotherapies using its proprietary FBDB™ platform and has been expanding collaborations to support clinical development and global partnering. The company has identified precision medicine and biomarker-guided development as central elements of its long-term strategy. Strategic Rationale HanchorBio gains access to clinical research expertise, translational data and biomarker resources that may support development of its oncology programmes, while the Taiwan Cancer Moonshot team expands its collaboration with an immunotherapy developer focused on precision oncology. Potential Impact If successful, the collaboration could strengthen evidence supporting biomarker-guided immunotherapy development and accelerate future clinical studies. Any impact on regulatory progress or commercialisation will depend on the results generated through the collaboration. Key Takeaway The collaboration aligns HanchorBio's immunotherapy pipeline with Taiwan's national precision oncology programme to support biomarker-driven cancer drug development. What to Watch Initial translational research outputs, incorporation of biomarker findings into ongoing clinical programmes and any expansion of the collaboration into additional oncology indications or clinical studies. Primary Source https://biopharmaapac.com/news/29/8302/hanchorbio-partners-with-taiwan-cancer-moonshot-team-to-advance-precision-immunotherapy.html Relevant Date 13 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Philips and Exor extend relationship agreement and raise ownership cap to 22%
The amended agreement strengthens Exor's long-term commitment to Philips while allowing the healthcare technology investor to increase its maximum shareholding from 20% to 22% Philips and Exor have agreed to extend their long-term relationship agreement and amend its terms to allow Exor to increase its maximum ownership stake in Philips from 20% to 22%. The revised agreement reinforces Exor's role as a long-term strategic shareholder while providing Philips with continued shareholder stability as it executes its healthcare technology strategy. Field Content Alert Type Deal Companies Royal Philips; Exor N.V. Deal Type Amendment and extension of relationship agreement Asset or Company Long-term strategic shareholding in Royal Philips Technology or Modality Healthcare technology Deal Value No financial consideration was disclosed. The amended agreement increases Exor's permitted maximum ownership stake from 20% to 22%. Geography Global What Happened Philips and Exor agreed to extend their existing relationship agreement, originally signed in 2023, while increasing the maximum ownership threshold Exor may hold from 20% to 22% of Philips' outstanding ordinary share capital. The agreement maintains Exor's position as a long-term minority shareholder and continues the governance framework established between the companies. No acquisition has taken place and the revised ownership limit does not require Exor to increase its holding. Why It Matters The amended agreement reinforces Philips' relationship with a long-term strategic investor while giving Exor additional flexibility to increase its investment if it chooses. For Philips, the arrangement supports continuity in governance and shareholder alignment as the company continues to focus on healthcare technology and long-term value creation. Supporting Context Exor became Philips' largest shareholder in August 2023 after acquiring a 15% stake and entering into a relationship agreement that permitted it to increase its ownership to a maximum of 20% while granting the right to nominate one Supervisory Board member. Strategic Rationale The extension confirms both parties' intention to continue their long-term partnership while providing Exor with greater investment flexibility without altering Philips' governance structure or strategic direction. Potential Impact If Exor increases its shareholding, Philips could benefit from an even more committed long-term investor. Any effect on corporate strategy or governance would remain subject to the existing terms of the relationship agreement and applicable regulations. Key Takeaway The amended agreement deepens Exor's long-term commitment to Philips by increasing its permitted ownership ceiling while preserving the existing strategic shareholder relationship. What to Watch Whether Exor chooses to increase its holding towards the new 22% limit and whether the extended relationship results in further governance or strategic collaboration announcements. Primary Source https://www.massdevice.com/philips-and-exor-extend-relationship-agreement-lift-ownership-cap-to-22/ Relevant Date 13 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Scotland backs UCB's Zilbrysq while NICE appraisal in England remains unresolved
The differing reimbursement positions highlight how health technology assessment decisions can diverge across UK nations, affecting the timing of patient access to new medicines. The Scottish Medicines Consortium (SMC) has accepted UCB's Zilbrysq (zilucoplan) for restricted use within NHS Scotland to treat adults with anti-acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis following a successful resubmission. In contrast, NICE has not yet issued final guidance for NHS England, leaving reimbursement decisions unresolved while its technology appraisal continues. Field Content Alert Type Industry Update Topic Health technology assessment (HTA) and market access Organisation(s) Scottish Medicines Consortium (SMC); National Institute for Health and Care Excellence (NICE); UCB Affected Stakeholders Patients with generalised myasthenia gravis, neurologists, NHS Scotland, NHS England, UCB and healthcare commissioners Therapy Area(s) Neurology; Generalised myasthenia gravis Geography United Kingdom (Scotland and England) What Happened The SMC accepted zilucoplan (Zilbrysq) for restricted use within NHS Scotland following a resubmission under its orphan equivalent medicine process, enabling access for eligible adults with anti-AChR antibody-positive generalised myasthenia gravis. At the same time, NICE has not completed its appraisal for NHS England, with final guidance still pending following further committee consideration, meaning routine NHS funding in England has not yet been confirmed. Why It Matters The differing decisions demonstrate that market access timelines can vary across UK healthcare systems even after regulatory approval. For manufacturers, clinicians and patients, reimbursement outcomes from HTA bodies remain a critical determinant of when new medicines become routinely available. Supporting Context Zilbrysq is indicated as an add-on to standard therapy for adults with anti-AChR antibody-positive generalised myasthenia gravis. The SMC previously did not recommend the medicine before accepting it following a resubmission, while NICE's appraisal has undergone multiple rounds of consultation and review. Who Is Most Affected Neurologists treating generalised myasthenia gravis and eligible patients in Scotland are most immediately affected through NHS access, while clinicians and patients in England continue to await NICE's final funding recommendation. Industry Impact The contrasting HTA outcomes reinforce the importance of country-specific evidence generation, pricing strategies and health economic submissions when seeking reimbursement across the UK. Future access in England will depend on NICE's final appraisal and any associated commercial arrangements. Key Takeaway The latest decisions illustrate how reimbursement for the same medicine can diverge across UK HTA bodies, influencing when patients gain routine NHS access. What to Watch NICE's final guidance for zilucoplan in England, expected following completion of its ongoing technology appraisal, and whether reimbursement becomes aligned across the UK. Primary Source https://scottishmedicines.org.uk/medicines-advice/zilucoplan-zilbrysq-ft-resub-smc2955/ Relevant Date 10 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Mereo grants Sentynl US option for alvelestat in deal worth up to $475 million
The agreement gives Sentynl an exclusive pathway to commercialise the Phase III-ready rare lung disease therapy in the US while providing global manufacturing rights and funding support for late-stage development. Mereo BioPharma has entered into an option and licence agreement with Sentynl Therapeutics for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), under which Mereo will receive a non-refundable option fee and, if the option is exercised, up to $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestones, plus tiered royalties on US sales. The agreement allows Mereo to retain commercial rights outside the United States while partnering with Sentynl to prepare the Phase III programme for a therapy that could become the first oral treatment for AATD-LD. Field Content Alert Type Deal Companies Mereo BioPharma Group plc; Sentynl Therapeutics (Zydus Lifesciences) Deal Type Option and licence agreement Asset or Company Alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) Therapy Area(s) Rare respiratory diseases; Pulmonology Technology or Modality Oral small-molecule neutrophil elastase inhibitor Deal Value Non-refundable option fee (undisclosed); if exercised, up to $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestone payments, plus double-digit tiered royalties on US net sales. Maximum disclosed potential value: up to $475 million, excluding royalties. Development Stage Phase III-ready Geography United States (commercial rights); Global manufacturing; Mereo retains commercial rights outside the US What Happened On 11 August 2026, Mereo BioPharma and Sentynl Therapeutics announced an option and licence agreement covering US commercial rights and global manufacturing rights for alvelestat in AATD-LD. Mereo will continue to lead global Phase III development and regulatory interactions until completion of the study, while the companies collaborate during the option period to refine the Phase III design and manufacturing strategy. The agreement remains contingent on Sentynl exercising its commercialisation option. Why It Matters The transaction provides Mereo with a development and commercial partner for the US market while allowing it to retain ex-US commercial rights. For Sentynl, the agreement expands its rare disease portfolio with a Phase III-ready programme targeting a rare genetic lung disease that currently has no approved oral treatment. Supporting Context Alvelestat is an oral neutrophil elastase inhibitor being developed for AATD-LD and has demonstrated positive Phase II efficacy in two studies. It has received FDA Fast Track designation and Orphan Drug Designation in both the US and EU. If approved, it could become the first oral therapy specifically indicated for AATD-LD. Strategic Rationale Mereo secures non-dilutive funding for late-stage development while retaining long-term commercial rights outside the US. Sentynl gains a late-stage rare disease asset that complements its existing portfolio and provides an opportunity to build its respiratory rare disease franchise. Potential Impact If the option is exercised and Phase III development is successful, the partnership could accelerate the introduction of a targeted oral therapy for AATD-LD while expanding Sentynl's presence in rare respiratory diseases. Clinical success and regulatory approval remain dependent on future trial outcomes. Key Takeaway The agreement combines late-stage development funding with a territory-specific commercial partnership, allowing Mereo to retain ex-US rights while positioning Sentynl to expand its rare disease portfolio in the United States. What to Watch Exercise of Sentynl's commercialisation option, refinement of the Phase III study design, initiation of the global Phase III programme in early 2027, and subsequent regulatory milestones. Primary Source https://www.sec.gov/Archives/edgar/data/1719714/000119312526343482/0001193125-26-343482.txt Relevant Date 11 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Medios agrees to acquire 74% of Caelo to expand European pharmaceutical ingredients business
The acquisition would add Caelo’s €40 million-revenue API and excipients business and establish the German company as the anchor of Medios’ planned European network for pharmaceutical compounding ingredients. Medios has signed an agreement to acquire a 74% majority stake in Caesar & Loretz (Caelo), a German supplier of active pharmaceutical ingredients, excipients and raw materials to pharmacies, hospitals and industrial customers, with financial terms not disclosed. The transaction would broaden Medios’ pharmacy offering while bringing Caelo together with existing operations in Belgium and Spain to form a European platform for APIs and excipients. Field Content Alert Type Deal Companies Medios AG; Caesar & Loretz GmbH (Caelo) Deal Type Acquisition of majority stake Asset or Company 74% majority stake in Caesar & Loretz GmbH (Caelo) Technology or Modality Active pharmaceutical ingredients (APIs), excipients and pharmaceutical raw materials Deal Value Financial terms have not been disclosed. Caelo expects revenue of approximately €40 million in the current financial year, but this represents company revenue rather than transaction consideration. (WebDisclosure) Geography Germany; Europe What Happened On 11 August 2026, Medios signed an agreement to acquire a 74% stake in Caelo, subject to antitrust approval. Caelo employs approximately 240 people at GMP-certified sites in Hilden and Bonn and supplies APIs, excipients and raw materials to pharmacies, hospitals and industrial customers. Following completion, Caelo will continue operating independently under its existing brand and management, with its Hilden and Bonn sites remaining its operational base. (WebDisclosure) Why It Matters The acquisition extends Medios’ offering further into the pharmaceutical supply chain, allowing it to provide pharmacies with finished medicines, sterile compounding services and ingredients for their own formulations. Caelo would also provide a German base for expanding Medios’ existing API and excipients activities across Europe, where common GMP standards allow these ingredients to be traded across borders. (WebDisclosure) Supporting Context Medios already operates in the API and excipients market through Magis Pharma in Belgium and Metapharmaceutical in Spain. Caelo would become the German anchor of these activities, which Medios plans to consolidate under its new Medios Holding Compounding Essentials GmbH structure. (WebDisclosure) Strategic Rationale Medios gains Caelo’s established pharmacy customer relationships, GMP-certified infrastructure and API and excipients portfolio, while Caelo gains access to Medios’ distribution network and international reach. The companies’ offerings are described as complementary rather than overlapping. (WebDisclosure) Potential Impact Medios intends to use the combined platform to broaden its product range and progressively extend its API and excipients activities into additional European markets. The acquisition is not expected to have a material impact on Medios’ 2026 Group forecast. (WebDisclosure) Key Takeaway The Caelo acquisition would give Medios a German anchor for a wider European API and excipients network while expanding the range of pharmaceutical products it can supply to pharmacies. What to Watch Antitrust approval and transaction completion, followed by further details on Medios’ European expansion plans; the company said additional information would be provided with its half-year report on 12 August 2026 and at its Capital Markets Day on 29 September 2026. (WebDisclosure) Primary Source https://www.webdisclosure.com/press-release/medios-ag-etr-medios-acquires-a-74-majority-stake-in-caelo-and-strengthens-its-german-and-european-business-in-active-pharmaceutical-ingredients-and-excipients-jN4ucmKNIi5 Relevant Date 11 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Alfasigma agrees to acquire Nordic Pharma to expand European specialty care business
The acquisition would add Nordic Pharma’s €190 million-revenue business and Nordimet rheumatoid arthritis franchise while expanding Alfasigma’s direct commercial presence to 18 European countries and adding platforms in Canada and Japan. Alfasigma has entered a share purchase agreement with SEVER Life Sciences to acquire 100% of Nordic Group B.V. (Nordic Pharma) and its subsidiaries, with financial terms not disclosed. The transaction would add Nordic Pharma’s rheumatoid arthritis, women’s health, critical care and ophthalmology portfolio while significantly expanding Alfasigma’s specialty-care commercial infrastructure across Europe and selected international markets. Field Content Alert Type Deal Companies Alfasigma; Nordic Group B.V. (Nordic Pharma); SEVER Life Sciences B.V. Deal Type Acquisition Asset or Company 100% of Nordic Group B.V. and its subsidiaries Therapy Area(s) Rheumatology; Women’s health; Critical care; Ophthalmology Deal Value Financial terms have not been disclosed. Nordic Pharma generated approximately €190 million in revenue in 2025, but this represents company revenue rather than transaction consideration. (Via Ritzau) Geography Europe; Canada; Japan What Happened On 11 August 2026, Alfasigma announced that it had entered into a share purchase agreement with SEVER Life Sciences to acquire 100% of Nordic Group B.V. and its subsidiaries. The transaction would add Nordic Pharma’s specialty pharmaceutical portfolio, including its Nordimet (methotrexate) rheumatoid arthritis franchise, as well as businesses in women’s health, critical care and ophthalmology. Nordic Pharma has direct operations in 18 European countries and commercial platforms in Canada and Japan, with approximately 265 employees. The acquisition remains subject to customary closing conditions, including required regulatory clearances. (Via Ritzau) Why It Matters Nordic Pharma adds an established specialty-care portfolio and commercial infrastructure that complements Alfasigma’s existing international expansion strategy. In rheumatology, Nordimet would sit alongside Alfasigma’s existing Jyseleca (filgotinib) franchise, while Nordic Pharma’s direct operations broaden the geographic infrastructure available to commercialise specialty and rare-disease medicines. (Via Ritzau) Supporting Context Alfasigma has been expanding its specialty and rare-disease portfolio through acquisitions and licensing, with particular focus on gastroenterology and immunology. Recent moves include its acquisition of Jyseleca in inflammatory diseases and a licensing agreement with GSK for linerixibat in cholestatic pruritus associated with primary biliary cholangitis. (Via Ritzau) Strategic Rationale Alfasigma gains Nordic Pharma’s rheumatoid arthritis franchise, additional specialty-care portfolios, 265 employees and direct commercial operations across multiple European markets, Canada and Japan. The transaction therefore combines portfolio expansion with a material increase in Alfasigma’s international commercial reach. (Via Ritzau) Potential Impact If completed, the acquisition could provide Alfasigma with a broader platform for launching and commercialising specialty and rare-disease medicines internationally, particularly across Europe. The eventual impact will depend on successful transaction completion and integration of Nordic Pharma’s portfolio and operations. Key Takeaway The Nordic Pharma acquisition would add approximately €190 million in annual revenue while giving Alfasigma a broader specialty-care portfolio and substantially larger direct commercial footprint across Europe and selected international markets. What to Watch Required regulatory clearances, completion of the acquisition and Alfasigma’s subsequent integration of Nordic Pharma’s portfolio, employees and international commercial operations. (Via Ritzau) Primary Source https://www.businesswire.com/news/home/20260804708645/en/ Relevant Date 11 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- aTyr Pharma cuts 60% of workforce to fund second Phase III study of efzofitimod in pulmonary sarcoidosis
The restructuring concentrates aTyr’s resources on a new late-stage study in patients with restrictive lung disease after its first Phase III trial missed its primary endpoint. aTyr Pharma is reducing its workforce by approximately 60% and prioritising resources towards a second Phase III study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The strategy narrows development to a subgroup in which post hoc analysis of the previous EFZO-FIT study suggested improvements in lung function and patient-reported outcomes, although those findings require prospective confirmation in the new trial. Field Content Alert Type Industry Update Topic Workforce restructuring; clinical development strategy Organisation(s) aTyr Pharma Affected Stakeholders aTyr Pharma employees; investors; clinical-development teams; investigators and patients involved in the efzofitimod programme Therapy Area(s) Pulmonology; Interstitial lung disease; Pulmonary sarcoidosis Geography United States; global clinical development What Happened In August 2026, aTyr Pharma announced a restructuring involving an approximately 60% reduction in its workforce as it focuses resources on a new Phase III study of efzofitimod in pulmonary sarcoidosis. The decision follows the September 2025 Phase III EFZO-FIT trial, which failed to meet its primary endpoint of reducing oral corticosteroid use versus placebo. Following a Type C meeting with the FDA, aTyr decided to pursue another Phase III study in a narrower population of patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The company submitted the planned study protocol to the FDA in June 2026. (aTyr Pharma) Why It Matters The restructuring illustrates the financial and development consequences of pursuing a second pivotal programme after an unsuccessful Phase III trial. Rather than abandoning efzofitimod, aTyr is concentrating capital on a more narrowly defined pulmonary sarcoidosis population identified through analysis of EFZO-FIT, making the next trial critical to the future of its lead programme. Supporting Context EFZO-FIT enrolled 268 patients and missed its primary steroid-reduction endpoint in September 2025. Subsequent analysis identified a subgroup of 44 patients with restrictive lung disease in whom the 5 mg/kg dose was associated with improvements in forced vital capacity and several patient-reported outcomes versus placebo; because this was a post hoc subgroup analysis, the findings do not establish efficacy and require prospective validation. (aTyr Pharma) Who Is Most Affected aTyr employees are directly affected by the 60% workforce reduction, while the company’s clinical-development organisation is becoming more concentrated around efzofitimod. Patients and investigators in pulmonary sarcoidosis are also relevant because the programme is continuing with a substantially narrower target population rather than being discontinued after the original Phase III result. Industry Impact aTyr’s strategy provides an example of a biotech using subgroup findings and regulatory discussions to redesign a pivotal programme following a Phase III miss. The approach carries significant development risk because the apparent benefit in restrictive lung disease was identified retrospectively and must now be demonstrated prospectively. Key Takeaway aTyr is making a substantial workforce reduction to preserve resources for a second attempt to establish efzofitimod’s efficacy in a more narrowly defined pulmonary sarcoidosis population. What to Watch The FDA’s response to the new Phase III protocol, initiation and financing of the study, and whether the prospective trial confirms the lung-function and patient-reported outcome signals observed in the restrictive-disease subgroup of EFZO-FIT. (aTyr Pharma) Primary Source aTyr Pharma corporate announcement and regulatory disclosures Relevant Date August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- BeOne and Revolution Medicines partner on RAS-targeted oncology combinations and Asian licensing deal
The collaboration pairs BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors while giving BeOne regional rights to the Revolution Medicines assets across selected Asian markets. BeOne Medicines and Revolution Medicines have entered a multi-part oncology collaboration covering combination studies involving BeOne pipeline assets and four clinical-stage RAS(ON) inhibitors — daraxonrasib, zoldonrasib, elironrasib and RMC-5127 — alongside exclusive regional development and commercialisation rights in selected Asian markets. The agreement combines BeOne’s development and regional commercial infrastructure with Revolution Medicines’ RAS-targeted portfolio and creates opportunities to evaluate new combination approaches for patients with RAS-addicted cancers. Field Content Alert Type Deal Companies BeOne Medicines; Revolution Medicines Deal Type Clinical development collaboration and regional licensing agreement Asset or Company Revolution Medicines’ daraxonrasib, zoldonrasib, elironrasib and RMC-5127; BeOne’s BGB-58067 and BG-T187 among the planned combination assets Therapy Area(s) Oncology; RAS-addicted cancers Technology or Modality RAS(ON) inhibitors; PRMT5 inhibitor; trispecific EGFR × MET × MET antibody Deal Value Financial terms were not fully disclosed. Revolution Medicines is eligible to receive development and sales milestone payments plus tiered royalties on net sales from the licensed Asian territories. Development Stage Clinical stage; the four Revolution Medicines RAS(ON) inhibitors are in clinical development, with BeOne also responsible for funding and conducting a global registrational Phase III trial for one of the assets. Geography Global clinical collaboration plus selected Asian markets for licensed rights. Revolution Medicines retains rights outside the licensed territories, including Japan and South Korea. What Happened On 11 August 2026, BeOne Medicines and Revolution Medicines announced a multi-part collaboration focused on RAS-addicted cancers. The companies plan to evaluate combinations of BeOne pipeline assets, including the MTA-cooperative PRMT5 inhibitor BGB-58067 and trispecific EGFR × MET × MET antibody BG-T187, with Revolution Medicines’ four clinical-stage RAS(ON) inhibitors: daraxonrasib, zoldonrasib, elironrasib and RMC-5127. Separately, Revolution Medicines granted BeOne exclusive development and commercialisation, or commercialisation-only rights depending on the territory, for the four RAS(ON) inhibitors in selected Asian markets. BeOne will also fund and conduct a global registrational Phase III trial for one of the Revolution Medicines assets. Why It Matters The agreement extends the development opportunities for Revolution Medicines’ RAS(ON) portfolio beyond monotherapy by testing combinations with mechanistically different oncology assets from BeOne. It also gives BeOne access to four clinical-stage RAS-targeted programmes across selected Asian markets, allowing the company to use its development and commercial infrastructure to support their regional development and potential launches. Supporting Context RAS alterations are important oncogenic drivers across multiple tumour types and have historically been difficult to target therapeutically. Revolution Medicines is developing RAS(ON) inhibitors designed to target active RAS proteins, while BeOne has a broader oncology pipeline containing potential combination partners with different mechanisms of action. Strategic Rationale Revolution Medicines gains access to BeOne’s oncology assets for combination studies while retaining development and commercial rights to its RAS(ON) programmes outside the licensed Asian territories. BeOne gains regional rights to four clinical-stage RAS inhibitors and the opportunity to evaluate its existing oncology pipeline in combinations that could potentially broaden the therapeutic application of both companies’ programmes. Potential Impact Successful studies could establish additional combination strategies for RAS-addicted cancers and broaden the development opportunities for both companies’ oncology pipelines. Any clinical or commercial impact will depend on trial results and subsequent regulatory approvals. Key Takeaway The collaboration combines BeOne’s oncology pipeline and Asian development infrastructure with four Revolution Medicines RAS(ON) inhibitors, creating both new combination programmes and a regional commercial partnership. What to Watch Initiation and results of the planned combination studies, identification of the RAS(ON) inhibitor selected for BeOne’s global registrational Phase III trial and subsequent development and regulatory progress across the licensed Asian territories. Primary Source BeOne Medicines / Revolution Medicines collaboration announcement Relevant Date 11 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Project Farma acquires SimoTech to expand GMP automation and digital manufacturing capabilities
The acquisition adds SimoTech’s automation engineering and digital manufacturing expertise to Project Farma’s existing life sciences manufacturing services, creating a broader offering spanning facility strategy through GMP operations. Project Farma, a PerkinElmer company, has acquired SimoTech, a specialist in automation, digital manufacturing and engineering services for the life sciences industry, with financial terms not disclosed. The acquisition expands Project Farma’s ability to support pharmaceutical and biotechnology manufacturers across automation strategy, system implementation, commissioning and ongoing GMP operations. Field Content Alert Type Deal Companies Project Farma; PerkinElmer; SimoTech Deal Type Acquisition Asset or Company SimoTech Technology or Modality GMP automation; digital manufacturing; manufacturing execution systems; process control and engineering services Deal Value Financial terms have not been disclosed. Geography United States; Ireland; global life sciences markets What Happened Project Farma, part of PerkinElmer’s OneSource Life Sciences business, has acquired SimoTech, an engineering company specialising in automation and digital manufacturing for pharmaceutical and biotechnology customers. The acquisition combines SimoTech’s expertise in areas including automation, manufacturing execution systems, digitalisation and GMP manufacturing systems with Project Farma’s existing capabilities across manufacturing strategy, capital projects, facility builds, technology transfer, commissioning, qualification and validation. Financial terms were not disclosed. Why It Matters Automation and connected manufacturing systems are increasingly integral to the design, commissioning and operation of GMP facilities. Adding SimoTech enables Project Farma to offer customers a more integrated service spanning physical manufacturing infrastructure and the automation and digital systems required to operate it, reducing the need to coordinate these capabilities across separate providers. Project Farma already provides automation, controls and validation services as part of its manufacturing offering. (Project Farma) Supporting Context Project Farma provides manufacturing and technical-operations consulting across biologics and advanced modalities, with more than 1,600 employees supporting projects in North America, Europe and Asia-Pacific. Its existing services cover the manufacturing lifecycle from strategy and facility construction through automation, validation, operational readiness and asset lifecycle management. (Project Farma) Strategic Rationale Project Farma gains SimoTech’s specialist automation and digital-manufacturing workforce and capabilities, complementing its existing facility, engineering, validation and technical-operations services. The combination is intended to provide life sciences customers with more continuous support from manufacturing strategy and facility development through automation implementation and GMP operations. Potential Impact The acquisition could increase Project Farma’s ability to compete for life sciences manufacturing programmes requiring integrated facility, automation and digital delivery, particularly as pharmaceutical manufacturers invest in connected and increasingly automated production environments. The commercial impact has not been disclosed. Key Takeaway Acquiring SimoTech expands Project Farma’s manufacturing offering deeper into GMP automation and digital systems, creating a more integrated technical-operations platform for pharmaceutical and biotechnology customers. What to Watch Integration of SimoTech into Project Farma and PerkinElmer’s OneSource Life Sciences organisation, including how its automation and digital manufacturing capabilities are deployed across Project Farma’s global customer base. Primary Source Press release issued by PerkinElmer/Project Farma: https://pressreleasehub.pa.media/article/project-farma-acquires-simotech-bringing-end-to-end-gmp-automation-and-digital-manufacturing-to-life-sciences-customers-80775.html Relevant Date August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com


